For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported mixed results for the fourth quarter after the closing bell on Monday. The company posted quarterly earnings of 46 cents per share which missed the ...
BioMarin Pharmaceutical's (NASDAQ: BMRN) website doesn't show any scheduled events on its calendar over the next month. However, that means nothing. The drugmaker will almost certainly report its 2025 ...
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Monday, 2026-02-23. Here's what investors need to know before the announcement. Analysts estimate that ...
Fintel reports that on January 20, 2026, Canaccord Genuity upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from Hold to Buy. As of January 13, 2026, the average one-year price ...
BioMarin Pharmaceutical ( (BMRN)) has shared an update. On December 19, 2025, BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valuing Amicus at approximately $4.8 ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 27, the US FDA approved BioMarin’s supplemental Biologics License ...
BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the best large cap stocks under $100 with huge upside potential. On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results